Table 1.
Characteristics of zoster vaccine live (ZVL) reports submitted to VAERS, May 2006–January 2015.
| Report characteristics | N (%) |
|---|---|
| Total reports | 23,092 |
| Serious1 | 972 (4) |
| Female | 15,469 (67) |
| ZVL given alone2 | 20,884 (90) |
| Type of reporter | |
| Manufacturer | 11,390 (49) |
| Healthcare provider | 6,408 (28) |
| Other | 3,463 (15) |
| Patient/parent | 1,831 (8) |
| Age groups (years) | |
| <503 | 877 (4) |
| 50–59 | 2,257 (10) |
| ≥604 | 15,683 (68) |
| Missing or unknown age | 4,275 (19) |
1
Includes death, life-threatening illness, hospitalization or prolongation of existing hospitalization, or permanent disability.
2
Among persons aged ≥50 years, when ZVL was given concomitantly with other vaccines, the most common vaccines included: inactivated influenza (53%), 23-valent pneumococcal polysaccharide (29%), and tetanus, diphtheria, pertussis (Tdap) (18%).
3
ZVL is not FDA approved for this age group.
4
When restricting analysis to reports where age was documented (n = 18,817), 83% were in persons aged ≥60 years.